Albireo Pharma, Inc. (ALBO) financial statements (2022 and earlier)
Company profile
| Business Address |
10 POST OFFICE SQUARE BOSTON, MA 02109 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 9/30/2016 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 248,107 | 251,272 | 131,843 | 163,885 | 53,231 | 29,931 | 28,684 | ||
| Cash and cash equivalents | 248,107 | 251,272 | 131,843 | 163,885 | 53,231 | 29,931 | 28,684 | ||
| Receivables | 3,272 | 2,915 | 726 | 370 | |||||
| Inventory, net of allowances, customer advances and progress billings | 194 | ||||||||
| Inventory | 194 | ||||||||
| Prepaid expense | 5,261 | ||||||||
| Other current assets | 12,096 | ||||||||
| Other undisclosed current assets | 10,593 | 9,956 | 850 | 1,054 | 560 | 151 | |||
| Total current assets: | 268,930 | 261,865 | 141,799 | 167,650 | 55,011 | 30,861 | 28,835 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 668 | 478 | 597 | 187 | 178 | 21 | |||
| Intangible assets, net (including goodwill) | 17,260 | 17,260 | 17,260 | 17,260 | 17,260 | 18,260 | 34 | ||
| Goodwill | 17,260 | 17,260 | 17,260 | 17,260 | 17,260 | 18,110 | |||
| Intangible assets, net (excluding goodwill) | 150 | 34 | |||||||
| Other noncurrent assets | 15,193 | 6,004 | 5,413 | 369 | 775 | 518 | |||
| Total noncurrent assets: | 33,121 | 23,742 | 23,270 | 17,816 | 18,213 | 18,799 | 34 | ||
| TOTAL ASSETS: | 302,051 | 285,607 | 165,069 | 185,466 | 73,224 | 49,660 | 28,869 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 42,467 | 24,334 | 18,271 | 12,517 | 7,455 | 8,520 | 696 | ||
| Accounts payable | 6,516 | 5,283 | 4,785 | 4,352 | 1,350 | 972 | 150 | ||
| Accrued liabilities | 35,951 | 19,051 | 13,486 | 8,165 | 6,105 | 7,548 | 192 | ||
| Employee-related liabilities | 354 | ||||||||
| Debt | 3,075 | ||||||||
| Derivative instruments and hedges, liabilities | 844 | ||||||||
| Restructuring reserve | 1,313 | ||||||||
| Other liabilities | 2,880 | 948 | 653 | 308 | 474 | 207 | |||
| Other undisclosed current liabilities | 62 | 62 | |||||||
| Total current liabilities: | 45,347 | 25,282 | 18,924 | 12,825 | 7,929 | 12,708 | 2,071 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 20,822 | 13,184 | 4,186 | ||||||
| Long-term debt, excluding current maturities | 10,004 | 9,621 | |||||||
| Operating lease, liability | 10,818 | 3,563 | 4,186 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt, including: | 10,960 | 3,579 | 4,270 | 35 | 42 | 358 | |||
| Other liabilities | 10,960 | 3,579 | 4,270 | 42 | 358 | ||||
| Other undisclosed liabilities, other than long-term debt | 35 | ||||||||
| Other undisclosed noncurrent liabilities | 49,314 | 62,331 | 44,528 | 49,969 | 1 | ||||
| Total noncurrent liabilities: | 81,096 | 79,094 | 52,984 | 50,004 | 42 | 359 | |||
| Total liabilities: | 126,443 | 104,376 | 71,908 | 62,829 | 7,971 | 12,708 | 2,430 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 175,608 | 181,231 | 93,161 | 122,637 | 65,253 | 36,952 | 26,439 | ||
| Common stock | 193 | 191 | 127 | 120 | 89 | 63 | 21 | ||
| Treasury stock, value | (230) | ||||||||
| Additional paid in capital | 475,390 | 456,472 | 245,769 | 214,694 | 114,522 | 61,338 | 288,469 | ||
| Accumulated other comprehensive income (loss) | 1,105 | (8,612) | 6,452 | 4,293 | 1,001 | 1,496 | |||
| Accumulated deficit | (300,850) | (266,820) | (159,187) | (96,470) | (50,359) | (25,945) | (262,051) | ||
| Total stockholders' equity: | 175,608 | 181,231 | 93,161 | 122,637 | 65,253 | 36,952 | 26,439 | ||
| TOTAL LIABILITIES AND EQUITY: | 302,051 | 285,607 | 165,069 | 185,466 | 73,224 | 49,660 | 28,869 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 40,579 | 8,308 | 9,636 | 12,740 | 1 | 11,364 | ||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 1 | 11,364 | ||
| Cost of revenue | (1,356) | |||||||
| Gross profit: | 39,223 | 8,308 | 9,636 | 12,740 | 1 | 11,364 | ||
| Operating expenses | (162,708) | (104,579) | (70,748) | (50,630) | (24,578) | (23,658) | (13,971) | |
| Operating loss: | (123,485) | (96,271) | (61,112) | (37,890) | (24,577) | (12,294) | (13,971) | |
| Nonoperating income (expense) | (10,423) | 14,573 | 3,691 | (3,363) | 335 | (2,675) | ||
| Foreign currency transaction gain (loss), before tax | (10,423) | 14,573 | (4,006) | (4,631) | ||||
| Loss from continuing operations before equity method investments, income taxes: | (133,908) | (81,698) | (57,421) | (41,253) | (24,242) | (14,969) | (13,971) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 99,878 | (25,935) | (5,296) | (4,838) | 40 | (1,319) | 268 | |
| Loss from continuing operations before income taxes: | (34,030) | (107,633) | (62,717) | (46,091) | (24,202) | (16,288) | (13,703) | |
| Income tax expense | (20) | (212) | (62) | (52) | ||||
| Net loss available to common stockholders, diluted: | (34,030) | (107,633) | (62,717) | (46,111) | (24,414) | (16,350) | (13,755) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (34,030) | (107,633) | (62,717) | (46,111) | (24,414) | (16,350) | (13,755) | |
| Other comprehensive income (loss) | 9,717 | (15,064) | 2,159 | 3,292 | (495) | 692 | ||
| Comprehensive loss, net of tax, attributable to parent: | (24,313) | (122,697) | (60,558) | (42,819) | (24,909) | (15,658) | (13,755) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.